Arrowhead Pharmaceuticals Inc (NAS:ARWR)
$ 25.84 -0.66 (-2.49%) Market Cap: 3.21 Bil Enterprise Value: 2.81 Bil PE Ratio: 0 PB Ratio: 6.63 GF Score: 54/100

Q4 2022 Arrowhead Pharmaceuticals Inc Earnings Call Transcript

Nov 28, 2022 / 09:30PM GMT
Release Date Price: $28 (-5.08%)
Operator

Ladies and gentlemen, welcome to Arrowhead Pharmaceuticals Conference Call. (Operator Instructions)

I will now hand the conference over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.

Vincent Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR & VP

Thank you, Justin. Good afternoon, everyone, and thank you for joining us today to discuss Arrowhead's results for its fiscal 2022 fiscal year ended December (sic) [September] 30, 2022. With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, our Chief Medical Officer, who will provide an update on our mid- and later-stage clinical pipeline; Dr. James Hamilton, our Senior Vice President of Discovery and Translational Medicine, who will provide an update on our earlier stage programs; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials.

In addition, Tracie Oliver, our Chief Commercial Officer; and Patrick O'Brien, our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot